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Original ArticleAngiopoietin-like protein 4 is an exercise-
induced hepatokine in humans, regulated by
glucagon and cAMPBodil Ingerslev 1,10, Jakob S. Hansen 1,2,10, Christoph Hoffmann 3, Jens O. Clemmesen 4, Niels H. Secher 5,
Mika Scheler 6,7, Martin Hrabĕ de Angelis 6,7,8, Hans U. Häring 3,7,9, Bente K. Pedersen 1, Cora Weigert 3,7,9,
Peter Plomgaard 1,2,*ABSTRACT
Objective: Angiopoietin-like protein-4 (ANGPTL4) is a circulating protein that is highly expressed in liver and implicated in regulation of plasma
triglyceride levels. Systemic ANGPTL4 increases during prolonged fasting and is suggested to be secreted from skeletal muscle following
exercise.
Methods: We investigated the origin of exercise-induced ANGPTL4 in humans by measuring the arterial-to-venous difference over the leg and
the hepato-splanchnic bed during an acute bout of exercise. Furthermore, the impact of the glucagon-to-insulin ratio on plasma ANGPTL4 was
studied in healthy individuals. The regulation of ANGPTL4 was investigated in both hepatic and muscle cells.
Results: The hepato-splanchnic bed, but not the leg, contributed to exercise-induced plasma ANGPTL4. Further studies using hormone infusions
revealed that the glucagon-to-insulin ratio is an important regulator of plasma ANGPTL4 as elevated glucagon in the absence of elevated insulin
increased plasma ANGPTL4 in resting subjects, whereas infusion of somatostatin during exercise blunted the increase of both glucagon and
ANGPTL4. Moreover, activation of the cAMP/PKA signaling cascade let to an increase in ANGPTL4 mRNA levels in hepatic cells, which was
prevented by inhibition of PKA. In humans, muscle ANGPTL4 mRNA increased during fasting, with only a marginal further induction by exercise. In
human muscle cells, no inhibitory effect of AMPK activation could be demonstrated on ANGPTL4 expression.
Conclusions: The data suggest that exercise-induced ANGPTL4 is secreted from the liver and driven by a glucagon-cAMP-PKA pathway in
humans. These ﬁndings link the liver, insulin/glucagon, and lipid metabolism together, which could implicate a role of ANGPTL4 in metabolic
diseases.
 2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords Diabetes; Insulin; Liver; Muscle; Myokine1. INTRODUCTION
Angiopoietin-like protein-4 (ANGPTL4) was identiﬁed in 2000 as a
secreted plasma protein expressed in adipose tissue [1] and liver [2].
ANGPTL4 is induced by fasting in both white adipose tissue and liver
under the regulation of peroxisome proliferator-activated receptors
(PPAR) [1]. ANGPTL4 regulates plasma triglyceride levels by
decreasing lipoprotein lipase (LPL) activity [3e6], promotes adipose
tissue lipolysis [7], and is suggested to improve glucose tolerance [8].
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substantiated by the ﬁnding that mice lacking ANGPTL4 have low
concentrations of triglycerides in plasma and increased LPL activity
[11].
In humans, ANGPTL4 is expressed in adipose tissue [12], intestine
[13], skeletal muscle [14], and, most abundantly, in liver [15]. Little is
known, however, about the origin of circulating ANGPTL4 in humans.
The liver may be the main contributor because of the high hepatic
ANGPTL4 mRNA level and a pronounced hepatic response to fasting
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been suggested [16,17]. Increased plasma ANGPTL4 in response to
exercise is considered to be muscle-derived, leading to the designation
“myokine” [17], but clear evidence for the release of ANGPTL4 from
muscles during or following exercise in humans is lacking.
Several regulatory mechanisms are suggested to increase the
expression of ANGPTL4, including free fatty acids (FFA) via PPAR
activation [18], glucocorticoid receptor signaling [19], and hypoxia
[20]. Fasting and exercise are important inducers of plasma ANGPTL4
attributed to the increase in circulating FFA [15]. Interestingly, insulin
has an inhibitory effect on both ANGPTL4 gene transcription in rodent
liver [21,22] and plasma levels of ANGPTL4 in humans [23]. However,
it is not known whether the inhibitory effect of insulin is direct or
secondary to its anti-lipolytic effect. A negative regulation of ANGPTL4
expression upon activation of AMPK is suggested in skeletal muscle
[17].
By assessing arterial-to-venous differences over the leg and the
hepato-splanchnic bed, we demonstrated that the increase in plasma
follistatin and FGF21 in exercising humans is liver-derived with no
contribution of the exercising leg [24e26]. Inspired by these obser-
vations, we investigated the origin of circulating ANGPTL4 in response
to acute exercise in healthy humans. We evaluated the regulation of
ANGPTL4 mRNA content in resting and exercising muscle and the
contribution of fasting. Finally, the glucagon-to-insulin ratio and cAMP-
dependent signaling as a potential driver of the exercise-induced in-
crease in circulating ANGPTL4 was examined.
2. MATERIAL AND METHODS
2.1. One-legged exercise
As described [26], nine healthy young males participated in this study.
A femoral artery catheter and bilateral femoral vein catheters were
inserted, and 2 h of knee-extensor exercise at 50% of maximum power
was followed by 3 h of rest. Blood samples were obtained regularly and
vastus lateralis needle biopsies obtained at time points 0, 2, 5 h, and
on the following morning. Femoral arterial blood ﬂow was measured by
Doppler ultrasound. The subjects fasted from 10 pm the day before
and remained fasted throughout the 5 h experimental period. The next
morning, subjects returned after an overnight fast for a muscle biopsy
and blood sample (24 h).
2.2. Exercise vs. fasting
Eighteen healthy male subjects were recruited and underwent a
medical examination. The subjects performed an incremental exercise
test on a cycle ergometer (Monark Ergomedic 839 E, Monark Ltd.,
Varberg, Sweden), and maximum oxygen uptake (VO2 max) was
determined by indirect calorimetry (Quark b2, CosMed, Rome). The
subjects were divided into an exercise group (n¼ 10) and a rest group
(n ¼ 8). Characteristics of the exercise group were: age 23.3  0.5
yrs., BMI 23.3  0.4 kg/m2, VO2 max 53.1  2.2 ml/kg/min, and for
the resting group: age 22.8  0.4 yrs., BMI 23.9  0.6 kg/m2, VO2
max 53.8  2.3 ml/kg/min.
The participants were asked to refrain from strenuous exercise 24 h
prior to the experimental day. On the experimental day, after an
overnight fast, a catheter was placed in an antecubital vein and
baseline blood samples drawn. The exercise trial (exercise group)
included 3 h of ergometer cycling exercise at an intensity corre-
sponding to 50% of VO2 max. Heart rate and VO2 were measured every
hour during exercise to control intensity. After the exercise, the sub-
jects rested supine for 6 h. Blood samples were drawn regularly and
muscle biopsies were obtained from the vastus lateralis muscle at time
0, 3, 6, 9 h, and the following morning (24 h). During the experimentalMOLECULAR METABOLISM 6 (2017) 1286e1295  2017TheAuthors. Published by ElsevierGmbH. This is an o
www.molecularmetabolism.comday, subjects remained fasted until the last blood sample was ob-
tained, but they had free access to water. In the control trial, the
subjects rested in the supine position throughout the 9 h of the trial
with blood samples and biopsies obtained at time points as described
for the exercise trial.
2.3. Hepatic venous catheter
This study is described in Ref. [24]. In brief, ten healthy males per-
formed 2 h of ergometer cycling at 60% of VO2 max in a semi-supine
position followed by 4 h of rest with catheters placed in an antecubital
vein, a hepatic vein, and a brachial artery, which allowed for arterial-
venous measurements over the liver. Hepatic plasma ﬂow was
measured as indocyanine green clearance before, during, and in re-
covery from exercise, and the production/clearance of ANGPTL4 was
calculated as described for FGF21 [24]. The subjects arrived after an
overnight fast and remained fasted throughout the trial, but they had
free access to water.
2.4. Hormone infusion
This study is also described in Ref. [24]. Ten healthy males went
through four experimental protocols after an overnight fast (test days
1e4). Trial 1: 1 h glucagon infusion (GlucaGen, Novo Nordisk) at 6 ng/
kg/min. Trial 2: 2 h somatostatin infusion (Octreotide, Hospira Nordic)
at 100 ng/kg/min (started 10 min prior to the glucagon infusion, in total
130 min) and 1 h glucagon infusion at 6 ng/kg/min. Trial 3: 2 h
(130 min) somatostatin infusion at 100 ng/kg/min (same as test day 2).
Trial 4: saline infusion at the same rate as the glucagon infusion rate. In
all four trials, the subjects remained fasted but had free access to
water.
2.5. Exercise with pancreatic clamp
As described in Ref. [27], six healthy male subjects underwent two
experimental protocols in randomized order: 1) 2 h of cycling at 60% of
VO2 max; 2) 2 h of cycling at 60% of VO2 max with a “pancreatic
clamp” (2 h of somatostatin infusion at 100 ng/kg/min with replace-
ment of glucagon 0.60 ng/kg/min and insulin 0.05 mU/kg/min). A
variable glucose infusion was applied to maintain a stable glucose
level. Data from one participant were removed from the analysis due to
unmeasurable high concentration of ANGPTL4 despite attempts with
multiple dilutions. A possible explanation is the presence of unspeciﬁc
autoantibodies in the samples.
2.6. Ethical committee approval
The studies were approved by the Scientiﬁc Ethics Committee of the
capital region of Denmark (one-legged exercise study [26]; acute ex-
ercise vs. fasting: H-4-2011-055; hormone infusion trial, and exercise
trial with liver vein catheterization [24] and exercise with the pancreatic
clamp [27]) in accordance with the Helsinki Declaration. All subjects
provided oral and written informed consent to participate.
2.7. Laboratory analysis
Blood samples were collected in tubes containing aprotinin for analysis
of glucagon and in tubes containing EDTA for other analyses. All blood
samples were spun immediately at 4 C at 3000 g for 15 min and the
plasma fraction was stored at80 C until analyses. Plasma ANGPTL4
was measured by commercially available Enzyme-Linked Immuno-
sorbant Assay (ELISA)-kit (BioVendor RD191073200R, Biovendor,
Brno, Czech Republic) with an intra-assay coefﬁcient of variation (CV)
of 3.2% and inter-assay CV of 7.0%. All samples were run in duplicate
in accordance with the protocol from the manufacturer. Free fatty acids
were measured by a commercially available enzymatic NEFA kit (Wakopen access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1287
Original ArticleDiagnostics, Richmond, USA) with intra-assay CV of 4.2% and inter-
assay CV of 8.5%. RNA was extracted from muscle biopsies as
described in Ref. [26]. Muscle ANGPTL4 mRNA content in the biopsies
was quantiﬁed by real time PCR using primers from Applied Biosystem:
cat# Hs01101127_m1 and was related to 18S RNA.
2.8. Cell cultures
Primary human skeletal muscle cells were obtained from the needle
biopsies of the vastus lateralis muscle and cultivated and fused to
myotubes [28]. The Ethical Committee of Tübingen University Med-
ical Department approved the protocol. For siRNA-mediated knock-
down, cells were transfected with siRNA oligonucleotides using
Viromer Blue (Lipocalyx, Halle, Germany) on day 5 of differentiation.
The ON-TARGET plus SMART-pool for PRKAA1, PRKAA2 (Dharma-
con, Thermo-Fisher Scientiﬁc, Waltham, MS, USA), and non-
targeting oligonucleotides for bacterial luciferase (sense: 50-
cguacgcggaauacuucga-30; antisense: 50-ucgaaguauuccgcguacg-30;
euroﬁns MWG/Operon; Ebersberg, Germany) were used at 20 nM.
Medium was changed after 24 h and cells were stimulated as
indicated. HepG2 cells (DMSZ, Braunschweig, Germany) were
cultivated in RPMI 1640 containing 11 mM glucose and 10% FBS,
1% glutamine, and 1% penicillin/streptomycin. Cells were starved
3 h in RPMI 1640 before substances were added. RNA isolation is
described in reference [29]. Quantitative real-time PCR (qRT-PCR)
was performed on a Roche LightCycler 480 using QuantiTect Primer
Assays Hs_ANGPTL4_1_SG, Hs_PRKAA1_1_SG, Hs_PRKAA2_1_SG,
Hs_PCK1_1_SG, HsG6PC_1_SG, Hs_ACTB_2_SG, and
Hs_TBP_1_SG (Qiagen, Hilden, Germany). Proteins were separated
by SDS polyacrylamide (7.5e15%) gradient gel electrophoresis.
Immunodetection on nitrocellulose membranes was performed with
antibodies against phospho-Thr-172 of AMPKa and phospho-Ser-79
of ACC (Cell Signaling Technology, Frankfurt, Germany), AMPKa1
and 2 (Upstate Biotechnology, Lake Placid, NY), ACC (Merck Milli-
pore, Billerica, MA).
2.9. Statistical analysis
Data are presented as mean  SEM. Differences between groups
were evaluated by a two- or three-way ANOVA. The group effect
was evaluated using the slice function by time in the mixed model.
Signiﬁcant effect of time was evaluated by a one-way ANOVA fol-
lowed by a Dunnett’s post hoc test. Release or uptake was calcu-
lated as arterial-to-venous difference and production/clearance
was calculated as the arterial-to-venous difference multiplied
with plasma ﬂow. These curves were further evaluated according to
the area under the curve by t-test as were the in vitro data.
The statistical analyses were performed by SAS 9.4 (Institute Inc.,
Cary, NC, USA) and a P < 0.05 was considered statistically
signiﬁcant.
3. RESULTS
3.1. One-legged exercise increases muscle ANGPTL4 transcripts
but not protein release from the leg
Two hours of one-legged exercise induced a 1.5-fold (P < 0.05)
increase in plasma ANGPTL4 followed by a further increase into the
recovery reaching 2.5-fold (P < 0.05) with no difference between
arterial and femoral venous blood (Figure 1A). The arterial-to-venous
difference showed no release or uptake of ANGPTL4 in the resting or
the exercising leg at any time (Figure 1B) and thus, no production or
clearance could be demonstrated (Figure 1C). ANGPTL4 mRNA
content increased in skeletal muscle; however, no difference could1288 MOLECULAR METABOLISM 6 (2017) 1286e1295  2017The Authors. Published by Elsevier GmbH.be detected between the ANGPTL4 mRNA content in the exercising
and resting leg (Figure 1D). Yet during recovery (time point 5 h),
ANGPTL4 mRNA in the exercised leg tended to increase further (7.4-
fold versus 3.1-fold) compared to the resting leg. The mRNA level
was back to baseline in both legs on the following morning (time
point 24 h).
To evaluate the separate effect of exercise and fasting on muscle
ANGPTL4 mRNA content, an overnight fast followed by 3 h of exercise
was compared with an overnight fast followed by rest. Irrespective of
preceding exercise or rest, muscle ANGPTL4 mRNA content increased
at 6 and 9 h of the trial (Supplemental Figure 1A) with no difference
detected between groups. The mRNA level returned to baseline in both
groups the following morning (24 h). Plasma FFA peaked with a 4.1-
fold (P < 0.05) increase at the end of exercise (3 h). The exercise
group had markedly higher plasma FFA during exercise and in the early
recovery, whereas during the resting trial a gradual increase was
observed reaching 1.7-fold (P < 0.05) after 9 h (Supplemental
Figure 1B). Plasma glucagon peaked at 2.3-fold at end of the exer-
cise (P < 0.05), whereas no change in glucagon could be detected
during the rest trial (Supplemental Figure 1C). In contrast, plasma
insulin decreasedw40% (P < 0.05) during exercise, whereas in the
rest trial insulin gradually decreased with a nadir at 9 h (Supplemental
Figure 1D).
3.2. The hepato-splanchnic bed contributes to circulating ANGPTL4
during exercise in humans
Since no release of ANGPTL4 from the legs could be demonstrated, we
investigated the contribution from the hepato-splanchnic bed to
exercise-induced plasma ANGPTL4 levels. ANGPTL4 increased 3.5-
fold (P < 0.05) during recovery from 2 h semi-supine cycling
(Figure 2A). Calculation of the arterial-to-venous difference (Figure 2B)
and the production (Figure 2C) over the hepato-splanchnic bed
revealed a release during recovery after exercise (one-way ANOVA
(P < 0.01)). The post hoc Dunnett’s test did reach borderline signiﬁ-
cance (P ¼ 0.08 and P ¼ 0.06, respectively, at time point 3 h). In
addition, the area under the curve (AUC) revealed a signiﬁcant
exercise-induced release 1820  426 mg  min/L (P < 0.05) and
production 2038  474 mg (P < 0.05).
3.3. Inhibition of glucagon-to-insulin ratio and FFA blunts exercise-
induced increase in plasma ANGPTL4
During exercise, both the increase in glucagon-to-insulin ratio and FFA
are blunted by a pancreatic clamp [27]. Young healthy male volunteers
performed a 2 h cycling exercise with a pancreatic clamp and e on a
different day e the same exercise with saline infused as control.
During the saline infusion, plasma ANGPTL4 increased 3.2-fold
(P < 0.05) in the recovery from exercise while the increase in
plasma ANGPTL4 was markedly reduced (a 1.4-fold; P < 0.05) with
the pancreatic clamp (Figure 3).
3.4. Regulation of plasma ANGPTL4 by the glucagon-to-insulin
ratio at rest
To evaluate whether an elevated glucagon-to-insulin ratio stimulates
exercise-induced increase in plasma ANGPTL4 levels, ANGPTL4 was
measured in samples from a hormone infusion study where the
exercise-induced increase in the glucagon-to-insulin ratio was
mimicked in resting healthy subjects [24]. When increasing the
glucagon-to-insulin ratio for 1 h by infusion of glucagon to a plasma
concentration of w100 pmol/L and reducing the insulin level by
infusion of somatostatin, an increase in plasma ANGPTL4 manifested
with similar kinetics to that developed in the recovery from exerciseThis is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 2: Hepato-splanchnic release of angiopoietin-like protein 4 (ANGPTL4) in
healthy human subjects during exercise. A: ANGPTL4 concentration in the artery (C)
and the hepatic vein (B) before, during (0e2 h) and into recovery after exercise (2e
6 h) (Two-way ANOVA, Time: P < 0.0001, Group: P ¼ 0.3727, Time  Group:
P ¼ 0.9883). B: Arterial-to-venous (mg/l) difference over the hepato-splanchnic bed. A
negative value indicates a release whereas a positive value indicates an uptake (One-
way ANOVA, Time: P ¼ 0.0017). C: Hepato-splanchnic production of ANGPTL4 is
calculated as arterial-to-venous difference multiplied by hepatic plasma ﬂow (mg/min)
(One-way ANOVA, Time: P ¼ 0.0014). A positive value indicates a release into the
circulation and a negative an uptake. #: Signiﬁcant changes from time point 0 h after an
2-way ANOVA followed by a Dunnett’s post hoc test. (*) designates a borderline sig-
niﬁcance of the post hoc Dunnett’s test at P ¼ 0.08 and P ¼ 0.06 respectively at time
point 3 h. The area under the curve for both arterial-to-venous difference (B) and
production (C) were signiﬁcantly different from zero (P < 0.05) by a t-test.
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Figure 1: Nine healthy male subjects performed 2 h (0e2 h) of one-legged knee
extensor exercise. A: Arterial (C) and femoral venous concentrations of angiopoietin-
like protein 4 (ANGPTL4) from both the resting (D) and the exercising (:) leg (the
curves are superimposed) (MANOVA, Time: P < 0.0001, Group: P ¼ 0.9929,
Time  Group: P ¼ 1.000). B: Arterial to venous differences over the resting (D) and
the exercising (:) leg of ANGPTL4 (Two-way ANOVA, Time: P ¼ 0.0073, Group:
P ¼ 0.6064, Time  Group: P ¼ 0.9954). C: Production (mg/min) or clearance of
ANGPTL4 from the resting (D) and the exercising (:) leg (Two-way ANOVA, Time:
P ¼ 0.1734, Group: P ¼ 0.4460, Time  Group: P ¼ 0.5284). D: ANGPTL4 mRNA
content in the skeletal muscle biopsies from both the resting (B) and the exercising
(C) leg (Two-way ANOVA, Time: P < 0.0001, Group: P ¼ 0.9761, Time  Group:
P ¼ 0.7075). #: Signiﬁcant changes from time point 0 h by a 2-way ANOVA followed by
a Dunnett’s post hoc test. P < 0.05 was considered signiﬁcant.
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in circulating ANGPTL4 (Figure 4A). When glucagon was administered
without somatostatin co-infusion, insulin increased following blood
glucose peak at w120 pmol/L [24] and no difference in plasma
ANGPTL4 between the glucagon and saline infusion was observed
(Figure 4B). Finally, infusion of only somatostatin that decreases
circulating insulin [24] resulted in a similar minor change in plasma
ANGPTL4 as the saline infusion (Figure 4C). The plasma FFA response
was assessed as a further stimulus for ANGPTL4. Increasing glucagon
for 1 h together with lowering of insulin by somatostatin resulted in a
FFA peak at 1 h. During the saline infusion, FFA increased gradually
(Figure 4D). When glucagon was administered without insulin inhibi-
tion, FFA was reduced due to the anti-lipolytic effect of insulin
(Figure 4E). Finally, with infusing somatostatin alone plasma FFA
increased (Figure 4F).
3.5. cAMP-protein kinase A signaling in HepG2 cells induces
ANGPTL4 mRNA expression
As glucagon increases cAMP and activates protein kinase A (PKA) in
hepatocytes, the response of ANGPTL4 mRNA to stimulation of this0
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rotein 4 (ANGPTL4) and free fatty acids (FFA) in resting healthy subjects (n ¼ 10). For
n plasma ANGPTL4 concentration by infusion of glucagon and somatostatin (C) (Two-
by infusion glucagon (C) (Two-way ANOVA, Time: P < 0.0001, Group: P ¼ 0.6127,
P ¼ 0.0004, Group: P ¼ 0.4160, Time  Group: P < 0.0001) (C) and by saline infusion
[24]. DeF: Changes in FFA concentration by infusion of glucagon and somatostatin (C)
by infusion of glucagon (C) (Two-way ANOVA, Time: P < 0.0001, Group: P ¼ 0.2870,
01, Group: P ¼ 0.0179, Time  Group: P < 0.0001) (F), and by saline (B) (DeF). $:
h time point by one-way ANOVA. P < 0.05 was considered signiﬁcant.
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pathway was evaluated using HepG2 cells. A cell-permeable cAMP
analogue and the adenylate cyclase activator forskolin increased
ANGPTL4 mRNA, which was reduced by two competitive inhibitors of
PKA (Figure 5A). Insulin also inhibited the forskolin-induced ANGPTL4
mRNA induction (Figure 5B). Regulation pattern of ANGPTL4 mRNA by
activators and inhibitors of the cAMP-PKA pathway is similar to the
regulation of the known cAMP target genes phosphoenolpyruvate
carboxykinase (Figure 5C) and glucose-6-phosphatase (Figure 5D).
Thus the hepatic ANGPTL4 production can be stimulated via the cAMP-
PKA pathway.
3.6. Inﬂuence of AMPK on ANGPTL4 mRNA regulation in human
muscle cells
It has been suggested that activation of AMPK suppresses the fatty
acid-dependent up-regulation of ANGPTL4 mRNA in skeletal muscle
following exercise resulting in lower ANGPTL4 mRNA content in the
exercising compared to the resting leg [17]. Since the present data do
not indicate such difference, the effect of AMPK activation on
ANGPTL4 abundance was studied in human primary muscle cells.
Cells were stimulated with palmitate for 24 h leading to induction of
ANGPTL4 mRNA (Figure 6A); however, this induction was not sup-
pressed by co-stimulating with the AMPK activator (A769662)
(Figure 6A). Treating muscle cells with only the AMPK activators
A769662 and AICAR for 3 or 24 h did not decrease but rather induced
a small increase in ANGPTL4 mRNA (Figure 6B). Activation of AMPK
was visualized as phosphorylation of AMPK and the AMPK substrate
ACC (Figure 6C). As reported previously, both AMPK activators in-
crease phosphorylation of ACC to a similar extend, while AICAR is
more effective than 100 mM A769662 to stimulate phosphorylation of
AMPK [30]. To further investigate the role of AMPK, the catalytic
subunits a1 and a2 were knocked-down by siRNA, and muscle cells
were stimulated with either palmitate or oleate. Figure 6D and E
display the efﬁciency of siRNA knock-down of AMPK catalytic subunit0,0
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Figure 5: Regulation of angiopoietin-like protein 4 (ANGPTL4), phosphoenolpyruvate carbo
the cAMP-protein kinase A (PKA) pathway. AeD: Cells were treated with 100 mM 8-(4-ch
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difference evaluated by t-test. P < 0.05 was considered signiﬁcant.
MOLECULAR METABOLISM 6 (2017) 1286e1295  2017TheAuthors. Published by ElsevierGmbH. This is an o
www.molecularmetabolism.coma1 and a2, respectively. The reduction of both AMPK catalytic
subunits a1 and a2, did not affect the palmitate- or oleate-mediated
induction of ANGPTL4 mRNA (Figure 6F). Taken together, the data do
not indicate that activation of AMPK inﬂuences ANGPTL4 mRNA
abundance in skeletal muscle.
4. DISCUSSION
This study demonstrates that e despite the fact that ANGPTL4 mRNA
levels increase in skeletal muscle after exercise e the protein is not
released to the circulation from either an exercising or a resting leg. In
contrast, the hepato-splanchnic bed contributed to the increase in
plasma ANGPTL4 after exercise. The hormone infusion and “pancreatic
clamp” studies suggest that increased glucagon-to-insulin ratio is a
potent stimulus for production of ANGPTL4 in the hepato-splanchnic
bed, and the in vitro HepG2 studies support that hepato-splanchnic
ANGPTL4 release is mediated by a cAMP-PKA dependent up-
regulation of ANGPTL4 mRNA abundance in hepatocytes.
During exercise pronounced up-regulation of ANGPTL4 mRNA takes
place in both liver [14,31] and skeletal muscle [14,17] of mice. Here
we provide in vivo evidence in humans for a release of ANGPTL4
from the liver during exercise, whereas the leg (e.g., skeletal
muscle) does not contribute. We did not evaluate the participation of
other tissues, e.g. the intestine, the spleen, or adipose tissue to the
exercise-induced increase in plasma ANGPTL4. The liver as source
for exercise-induced ANGPLT4 is in line with the ﬁnding of glucagon
as the stimulus, particularly because skeletal muscle does not
exhibit relevant glucagon receptor expression [32]. The ﬁnding adds
ANGPTL4 to the list of exercise-regulated human “hepatokines”,
including FGF21 [24] and follistatin [25], and mRNA data in mice
suggest that exercise is a profound stimulus for the liver to secrete
metabolically active factors e factors which may act on other tis-
sues in an endocrine fashion [33]. Based on hepatic mRNAs F Ins + F
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Original Articleabundance in mice, the liver is also likely to be an important source
of plasma ANGPTL4 at rest and during fasting [15]. However, prior
to exercise no detectable release of ANGPTL4 was demonstrated in
this study, suggesting that the hepato-splanchnic bed is not the only
tissue releasing ANGPTL4 to the circulation. Due to the high mRNA1292 MOLECULAR METABOLISM 6 (2017) 1286e1295  2017The Authors. Published by Elsevier GmbH.content of ANGPTL4 in subcutaneous adipose tissue [1,12], it could
be that fat tissue is a source of circulating ANGPTL4 during fasting.
We provide evidence for activation of the cAMP/PKA pathway regu-
lating ANGPTL4 expression. In experimental models, PPARa, PPARd
[1], and glucocorticoid receptor signaling [19] up-regulate ANGPTL4This is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mRNA. The data obtained both in vivo and in vitro provide evidence for
a contribution of glucagon-dependent activation of the cAMP/PKA
pathway to exercise-induced increase in ANGPTL4. Since an elevated
glucagon-to-insulin ratio in vivo is accompanied by increased circu-
lating FFA we could not differentiate between the two stimuli. However,
regulation and kinetics of plasma FFA, were not paralleled by changes
in plasma ANGPTL4. Of note, increasing FFA in 6 h in resting subjects
has been demonstrated to increase plasma ANGPTL4 [15]; however,
elevation of FFA for 6 h also induces insulin resistance.
Infusion of somatostatin alone resulted in increased FFA (Figure 4F),
but had no effect on plasma ANGPTL4 (Figure 4C). The up-regulation of
plasma ANGPTL4 occurs 1e2 h after the peak in the glucagon-to-
insulin ratio (Figure 4A), pointing to transcriptional regulation. The
cell culture experiments support that cAMP-mediated activation of PKA
increases ANGPTL4 mRNA. The results are in accordance with data
obtained in white and brown adipocytes, showing that b-adrenergic
stimulation increases cAMP and ANGPTL4 mRNA and protein abun-
dance [34]. There is little information about how the cAMP/PKA-
dependent pathway activates ANGPTL4 expression. Activation of PKA
increases the transcriptional activity of PPARs by mechanisms
involving stabilization of the PPAR/RXR/DNA binding, but also by po-
tential interaction with other cofactors [35]. During exercise,
epinephrine activates the adenylyl cyclase and also leads to increased
cAMP in hepatocytes, which may add to ANGPTL4 stimulation. The
inhibitory effect of insulin, which is suppressed during exercise, seems
to play an additional role in up-regulation of ANGPTL4, as glucagon
infused without somatostatin does not induce an increase in ANGPTL4.
Also, cortisol increases during exercise, but in humans prednisolone
seems to reduce circulating ANGPTL4 [23], making cortisol an unlikely
mediator of exercise-induced ANGPTL4.
The increase in ANGPTL4 mRNA in skeletal muscle without a release
to the circulation suggests a para/autocrine function. ANGPTL4 pro-
tein is detected in muscle tissue by ELISA and with immunoﬂuo-
rescence staining [17] and is released to the media of primary human
myotubes upon electric pulse stimulation [29]. ANGPTL4 may interact
locally with LPL, which is also increased in skeletal muscle biopsies
after a short-term fast together with PDK4, UCP3, and CPT1 [36].
ANGPTL4 inhibits LPL activity on the surface of capillary endothelial
cells within muscle tissue [37], and interactions between ANGPTL4
and LPL were also observed intracellularly [6,12]. Another possible
function of intramuscular ANGPTL4 production is regulation of
angiogenesis as suggested in relation to neovascularization and
tendon healing [38]. Of note, increased muscle mRNA or enhanced
intramuscular protein release has been shown for other secreted
factors such as IL-8 or VEGF which do not necessarily translate into
higher systemic levels [39,40]. On the other hand, we cannot exclude
a contribution of muscle ANGPTL4 to plasma concentrations under
other circumstances.
In vitro, we did not observe the previously reported inhibitory effect of
AMPK activation on ANGPTL4 mRNA in skeletal muscle cells [17]. With
a similar approach, using the same concentration of AICAR (1 mM) and
short-term (3 h) as well as long-term (24 h) treatment, no reduction of
ANGPTL4 mRNA content was observed. A comparable conclusion was
reached using the AMPK activator A769662 and knocking-down the
catalytic subunits of AMPK. In contrast to cell culture experiments in
murine C2C12 myotubes, we studied human myotubes. Down-
regulation of ANGPTL4 by AMPK activation is tissue-speciﬁc, as
demonstrated in brown but not white adipose tissue [34]. Thus,
different results obtained in human and murine myotubes could be
expected. We conclude that AMPK activation in exercising human
muscles does not interfere with ANGPTL4 mRNA expression.MOLECULAR METABOLISM 6 (2017) 1286e1295  2017TheAuthors. Published by ElsevierGmbH. This is an o
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exercise are inconsistent [14,17]. Norheim et al. found increased
ANGPTL4 mRNA in response to exercise before and after 12 weeks of
training [14]. Catoire et al. also applying one-legged exercise, but
without assessment of the arterial-to-venous difference e found no
increase in ANGPTL4 mRNA in muscle in the exercising leg but only in
the resting leg [17]. In both studies, no control for the effect of the
short-term fasting was included. The present data underline the
importance of the control setting because an overnight fast followed by
exercise led to an almost identical increase in skeletal muscle
ANGPTL4 mRNA as that of an overnight fast followed by rest. ANGPTL4
is increased by short-term fasting in skeletal muscle and when
combined with acute exercise no major additive or inhibitory effects
are observed.
ANGPTL4 is a mediator of hyperplasia of pancreatic a-cells [41],
suggesting a feedback loop to the endocrine pancreas. Hence, con-
ditions affecting the sensitivity to insulin and glucagon such as the
metabolic syndrome and type 2 diabetes could be expected to dys-
regulate ANGPTL4. The metabolic syndrome and type 2 diabetes are
characterized by insulin resistance that could increase ANGPTL4.
Notably, ANGPTL4 mRNA abundance in adipose tissue is reduced in
response to a hyperinsulinemic-euglycemic clamp in healthy subjects
but not in patients with type 2 diabetes [42]. Circulating levels of
ANGPTL4 are also related to markers of the metabolic syndrome [43]
and are elevated in type 2 diabetes [44]. Thus, impaired insulin
sensitivity is associated with elevated circulating ANGPTL4.
5. CONCLUSION
In conclusion, ANGPTL4 is released from the hepato-splanchnic bed
but not the leg during exercise. The glucagon-to-insulin ratio is
identiﬁed as an important regulator of ANGPTL4 plasma in humans,
probably involving cAMP-PKA-driven hepatic ANGPTL4 expression.
Further insight into the effects of hepatic release of ANGPTL4 could be
of great value to understand exercise-induced inter-organ crosstalk.
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